Tryptophan as a Modulating Factor in the Antimigraine Efficacy of Triptans
Recruiting · NCT07177885 · Observational (researchers observe without assigning treatment) · Lead sponsor: University Hospital, Clermont-Ferrand
View the official record on ClinicalTrials.gov →Interventions studied
What this trial is about
Migraine is a leading cause of disability, and while triptans are commonly used to treat migraine attacks, over 20% of patients don't respond well to them. This study aims to understand why some people don't benefit from triptans. One key focus is tryptophan, an amino acid that plays a role in migraine and is involved in producing serotonin, which affects pain and inflammation. The study will compare levels of tryptophan and its by-products in patients who respond well to triptans versus those who don't. It will also look at how conditions like inflammatory bowel disease may affect tryptophan absorption. The goal is to improve migraine treatments tailored to different patient needs, though participants may not experience immediate personal benefits.
Who can take part
Inclusion criteria
- Cisgender women, premenopausal, aged 18 to 50 years.
- Cisgender men, aged 18 to 50 years.
- Diagnosed with migraine (according to ICHD-3 criteria).
- Diagnosed as responders or non-responders to triptans (according to the criteria of Sacco et al., 2022).
- Permitted comparison groups include: triptans used alone or in combination with other migraine treatments (e.g., NSAIDs, acetaminophen, ergotamine, opioids, antiemetics).
- All routes of administration and all dosages.
- Affiliation with a social security system.
Exclusion criteria
- Patients under guardianship, curatorship, deprivation of liberty, or legal protection
- Pregnant and breastfeeding women
Where it is running
1 location listed.
- CHU de Clermont-Ferrand - Clermont-Ferrand, France